8-K
Acadia Healthcare Company, Inc. (ACHC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 5, 2025 (August 4, 2025)
Acadia Healthcare Company, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 001-35331 | 45-2492228 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 6100 Tower Circle, Suite 1000<br><br> <br>Franklin, Tennessee<br><br> <br>(Address of Principal Executive Offices) | 37067<br><br> <br>(Zip Code) | |
| --- | --- |
(615) 861-6000
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | ACHC | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) issued a press release announcing, among other things, Acadia’s operating and financial results for the second quarter ended June 30, 2025. The press release is furnished herewith as Exhibit 99 hereto and is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Executive Vice President and Chief Financial Officer
On August 4, 2025, Heather Dixon notified the Company of her resignation as Executive Vice President and Chief Financial Officer, effective August 15, 2025. Ms. Dixon’s separation from the Company is not a result of any disagreement with other members of the Company’s management or the Company’s external auditor.
Appointment of Interim Chief Financial Officer
The Board of Directors of the Company has appointed Timothy Sides to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”), effective August 16, 2025. The Company intends to conduct a nationwide search for a permanent chief financial officer.
Mr. Sides, age 47, has been employed by the Company since February 2020, most recently as Senior Vice President, Operations Finance. Prior to that, Mr. Sides served in the role of Operations Group Chief Financial Officer. Prior to joining the Company, Mr. Sides was employed in various financial roles at Universal Health Services, Inc. from November 2013 to February 2020.
There is no arrangement or understanding between Mr. Sides and any other person pursuant to which Mr. Sides was selected as the Company’s Interim CFO. Mr. Sides has no family relationships with any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Sides is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Mr. Sides’ annual base salary is $445,000 and, for his service as Interim CFO, he will receive a supplemental payment of $6,140 for every week that he serves as Interim CFO. Mr. Sides will continue to be eligible for the cash incentive program established for his prior role for 2025, pursuant to which he is eligible to receive an amount equal to 75% of his base salary at target level performance for the year. Mr. Sides’ supplemental payment will be included when calculating his cash incentive for 2025. Mr. Sides is eligible for benefits generally available to officers of the Company.
Mr. Sides’ previous cash retention award opportunity is being amended in connection with his appointment as Interim CFO to provide an opportunity to earn a cash retention bonus of $500,000 if Mr. Sides remains continuously employed by the Company through March 31, 2026. Pursuant to the terms of the cash retention award agreement, if the Company terminates his employment without cause prior to March 31, 2026, then Mr. Sides shall be entitled to the full amount of the retention bonus provided that he executes a customary release of claims.
2
Mr. Sides is party to a Severance Agreement with the Company, dated as of April 29, 2022. The Severance Agreement provides that if Mr. Sides is terminated without cause or resigns with good reason, he is generally entitled to receive (subject to the satisfaction of certain conditions) (i) a severance payment equal to 12 months of his base salary, payable under the Company’s regular payroll practices; (ii) accelerated vesting of restricted stock awards; (iii) any unused and unpaid time off accrued through the termination date; and (iv) an amount equal to the cost of the premiums for continued health and dental insurance for Mr. Sides and his dependents in accordance with COBRA for 12 months. The Severance Agreement contains restrictive covenants pursuant to which Mr. Sides has agreed not to compete with the Company during his period of employment and for 12 months thereafter. The agreement also contains non-solicitation and non-disparagement covenants consistent with other officers of the Company.
The foregoing descriptions of the cash retention award agreement and the Severance Agreement do not purport to be complete and are qualified in their entirety by the terms and conditions of the applicable agreements, as amended, the forms of which have been or will be filed as exhibits to the Company’s reports filed with the Securities and Exchange Commission.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
|---|---|
| 99 | Press Release of Acadia Healthcare Company, Inc., dated August 5, 2025 |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| --- | --- |
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 5, 2025 | ACADIA HEALTHCARE COMPANY, INC. | |
|---|---|---|
| By: | /s/ Brian P. Farley | |
| Brian P. Farley | ||
| Executive Vice President, Secretary and General Counsel |
4
ex_848443.htm
Exhibit 99
ACADIA HEALTHCARE REPORTS SECOND QUARTER 2025 RESULTS
Provides Updated Guidance for 2025; Announces Chief Financial Officer Transition
FRANKLIN, Tenn. (August 5, 2025) – Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2025.
Second Quarter 2025 Highlights
| ● | Revenue totaled $869.2 million, an increase of 9.2% over the second quarter of 2024 |
|---|---|
| ● | Same facility revenue increased 9.5% compared with the second quarter of 2024, including an increase in revenue per patient day of 7.5% and an increase in patient days of 1.8% |
| --- | --- |
| ● | Net income attributable to Acadia totaled $30.1 million, or $0.33 per diluted share |
| --- | --- |
| ● | Adjusted income attributable to Acadia totaled $74.8 million, or $0.83 per diluted share |
| --- | --- |
| ● | Adjusted EBITDA increased 7.6% to $201.8 million in the second quarter |
| --- | --- |
| ● | Added 101 newly licensed beds to existing facilities in the second quarter |
| --- | --- |
Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 9.
Second Quarter Results
Chris Hunter, Chief Executive Officer of Acadia, remarked, “Our results for the second quarter of 2025 reflect solid execution of our growth strategy as we continued to address the critical demand for behavioral health services in the United States. Revenue for the second quarter increased 9.2% over the second quarter last year, and Adjusted EBITDA improved 7.6% over the prior-year period. Importantly, we have made significant progress to date in 2025 in meeting our stated goals for bed additions and expanding access to care. With our proven operating model and strong focus on clinical quality, Acadia is uniquely positioned across the care continuum to fill a critical gap for evidence-based specialized behavioral health services. As we continue to expand our market reach, we also remain focused on strengthening our capabilities and leveraging technology to drive greater efficiencies in care delivery and deliver favorable clinical outcomes. We are proud of the important work we are doing, and we commend our extraordinary team of dedicated employees and clinicians across Acadia who continue to provide safe, quality patient care for those seeking treatment for mental health and substance use issues.”
In the second quarter of 2025 the Company recognized a favorable pre-tax benefit of $51.8 million associated with the recently approved state supplemental program in Tennessee, including $28.5 million related to fiscal year 2024, $11.0 million related to the first quarter of 2025, and $12.3 million related to the second quarter of 2025. This compares to $8.6 million of total net pre-tax benefit from similar programs in the state of Tennessee recognized in the second quarter of 2024.
Also included in results for the second quarter of 2025 were $14.2 million of startup losses associated with newly constructed facilities, compared to $4.6 million in the second quarter of 2024.
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 2
August 5, 2025
Strategic Investments for Long-Term Growth
During the second quarter of 2025, the Company continued to make progress in meeting its strategic growth objectives, adding 101 beds to existing facilities, bringing the total to 191 beds added to existing facilities for the first half of 2025. Including the 288 beds added to newly constructed facilities in the first quarter, the Company has added a total of 479 beds to date in 2025.
In addition, Acadia added four new comprehensive treatment centers (“CTCs”), extending the Company’s market reach to 174 CTCs across 33 states, treating over 74,000 patients daily in this critical area of care.
Acadia has 21 joint venture partnerships for 22 hospitals, with 13 hospitals already in operation and nine additional hospitals expected to open in the coming years, including three expected to open later this year.
Cash and Liquidity
Acadia has continued to maintain a strong financial position with sufficient capital to make strategic investments in its business. As of June 30, 2025, the Company had $131.4 million in cash and cash equivalents and $828.3 million available under its $1.0 billion revolving credit facility.
During the second quarter of 2025, the Company repurchased 103,939 shares for a total of $3.2 million, bringing total year-to-date repurchases to 1,706,625 shares for a total of $50.4 million.
2025 Financial Guidance
Acadia today updated its previously announced financial guidance for 2025, as follows:
| 2025 Guidance Range | |
|---|---|
| Revenue | $3.3 to $3.35 billion |
| Adjusted EBITDA | $675 to $700 million |
| Adjusted earnings per diluted share | $2.45 to $2.65 |
| Interest expense | $130 to $140 million |
| Tax rate | 25% to 26% |
| Depreciation and amortization expense | $185 to $195 million |
| Stock compensation expense | $40 to $45 million |
| Operating cash flows | $460 to $485 million |
| Expansion capital expenditures | $495 to $535 million |
| Maintenance and IT capital expenditures | $105 to $115 million |
| Total bed additions | 950 to 1,000 beds |
The Company’s full-year guidance includes the following assumptions:
| ● | Same-facility volume growth in the range of 2 to 3 percent. |
|---|---|
| ● | Same-facility revenue per patient day growth in the low single digits. |
| --- | --- |
| ● | Startup losses in the range of $60 to $65 million, for the full year 2025 related to newly opened facilities. The $10 million increase relative to prior expectations is primarily a result of current year facility construction running ahead of schedule. |
| --- | --- |
| ● | A net increase in Medicaid supplemental payments of $30 to $40 million for the full year 2025. This includes a $10 million to $11 million per quarter recurring benefit related to the new Tennessee program in the second half of the year. |
| --- | --- |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 3
August 5, 2025
The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.
Chief Financial Officer Transition
Acadia also announced that Heather Dixon will be stepping down from her role as Chief Financial Officer, effective August 15, 2025, to pursue the role of President and Chief Operating Officer at another company. Tim Sides, who currently serves as Senior Vice President, Operations Finance, will serve as interim Chief Financial Officer while the Company undertakes a search for a permanent replacement.
“We are grateful for Heather’s leadership and contributions over the past two years. Heather played a key role in strengthening our financial foundation and supporting our growth strategy,” said Hunter. “As she moves on to pursue this new opportunity, we extend our sincere thanks to Heather and wish her well. We are fortunate to have a strong finance leadership team to take on additional responsibilities and help ensure a smooth transition during our search.”
“It has been a privilege working with Chris, the Board, and the leadership team of Acadia. I am proud of the work we’ve done together, and I believe Acadia is positioned well for continued success,” said Dixon.
Sides joined Acadia in February of 2020 and has served as the Senior Vice President, Operations Finance since June of 2023. In this role, Sides holds supervisory responsibilities for the operational finance teams for all of the Company’s lines of business, cash management, government reimbursement, revenue cycle and procurement. He is also highly involved in driving financial and operational improvements across Acadia.
Conference Call
Acadia will hold a conference call to discuss its second quarter financial results at 8:00 a.m. Central Time/9:00 a.m. Eastern Time on Wednesday, August 6, 2025. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of June 30, 2025, Acadia operated a network of 274 behavioral healthcare facilities with approximately 12,100 beds in 39 states and Puerto Rico. With approximately 25,000 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 4
August 5, 2025
Forward-Looking Information
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements related to our strategy, growth, anticipated operating results for future periods and our share repurchase program. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (“OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.
Share Repurchase Authorization Disclaimer
Acadia’s share repurchase program permits the Company to make repurchases on a discretionary basis as determined by management, subject to market conditions, applicable legal requirements, available liquidity, compliance with the Company's debt agreements, and other appropriate factors. Repurchases under the share repurchase program are to be made through open market or privately negotiated transactions and may be made pursuant to plans entered into in accordance with Rule 10b5-1 and/or Rule 10b-18 of the Exchange Act. The share repurchase program does not have a termination date, does not obligate Acadia to acquire any particular amount of common stock, and may be modified, extended, suspended, or discontinued by the Company’s Board of Directors at any time without prior notice. No assurance can be given that any particular amount of common stock will be repurchased.
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 5
August 5, 2025
| Acadia Healthcare Company, Inc. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Condensed Consolidated Statements of Income | |||||||||||
| (Unaudited) | |||||||||||
| Six Months Ended June 30, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2024 | 2025 | 2024 | |||||||||
| Revenue | 869,232 | $ | 796,040 | $ | 1,639,737 | $ | 1,564,091 | ||||
| Salaries, wages and benefits (including equity-based compensation expense of 10,549, 8,869, 19,226 and 17,547, respectively) | 452,417 | 419,757 | 897,688 | 837,280 | |||||||
| Professional fees | 49,961 | 48,050 | 95,668 | 93,738 | |||||||
| Supplies | 28,532 | 27,878 | 56,874 | 54,530 | |||||||
| Rents and leases | 12,610 | 11,889 | 24,266 | 23,752 | |||||||
| Other operating expenses | 134,414 | 109,690 | 248,416 | 210,763 | |||||||
| Depreciation and amortization | 48,995 | 36,066 | 96,027 | 72,413 | |||||||
| Interest expense, net | 35,138 | 29,159 | 64,320 | 56,373 | |||||||
| Debt extinguishment costs | — | — | 1,269 | — | |||||||
| Legal settlements expense | — | — | 3,504 | — | |||||||
| Loss on impairment | 1,452 | 1,000 | 1,452 | 1,000 | |||||||
| Gain on sale of property | (8,715 | ) | — | (8,715 | ) | — | |||||
| Transaction, legal and other costs | 64,425 | 6,091 | 95,497 | 8,938 | |||||||
| Total expenses | 819,229 | 689,580 | 1,576,266 | 1,358,787 | |||||||
| Income before income taxes | 50,003 | 106,460 | 63,471 | 205,304 | |||||||
| Provision for income taxes | 12,067 | 25,643 | 16,471 | 45,717 | |||||||
| Net income | 37,936 | 80,817 | 47,000 | 159,587 | |||||||
| Net income attributable to noncontrolling interests | (7,809 | ) | (2,335 | ) | (8,499 | ) | (4,722 | ) | |||
| Net income attributable to Acadia Healthcare Company, Inc. | 30,127 | $ | 78,482 | $ | 38,501 | $ | 154,865 | ||||
| Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: | |||||||||||
| Basic | 0.33 | $ | 0.86 | $ | 0.42 | $ | 1.69 | ||||
| Diluted | 0.33 | $ | 0.85 | $ | 0.42 | $ | 1.68 | ||||
| Weighted-average shares outstanding: | |||||||||||
| Basic | 90,328 | 91,628 | 90,987 | 91,495 | |||||||
| Diluted | 90,435 | 92,043 | 91,400 | 92,051 |
All values are in US Dollars.
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 6
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||
|---|---|---|---|---|
| Condensed Consolidated Balance Sheets | ||||
| (Unaudited) | ||||
| June 30, | December 31, | |||
| --- | --- | --- | --- | --- |
| 2025 | 2024 | |||
| (In thousands) | ||||
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 131,421 | $ | 76,305 |
| Accounts receivable, net | 408,540 | 365,339 | ||
| Other current assets | 151,599 | 135,848 | ||
| Total current assets | 691,560 | 577,492 | ||
| Property and equipment, net | 3,063,523 | 2,853,193 | ||
| Goodwill | 2,276,232 | 2,264,851 | ||
| Intangible assets, net | 79,468 | 70,003 | ||
| Deferred tax assets | 25,383 | 20,964 | ||
| Operating lease right-of-use assets | 112,743 | 118,369 | ||
| Other assets | 59,450 | 52,043 | ||
| Total assets | $ | 6,308,359 | $ | 5,956,915 |
| LIABILITIES AND EQUITY | ||||
| Current liabilities: | ||||
| Current portion of long-term debt | $ | 20,313 | $ | 76,816 |
| Accounts payable | 219,824 | 232,704 | ||
| Accrued salaries and benefits | 155,720 | 155,426 | ||
| Current portion of operating lease liabilities | 22,591 | 25,462 | ||
| Other accrued liabilities | 105,264 | 87,511 | ||
| Total current liabilities | 523,712 | 577,919 | ||
| Long-term debt | 2,247,027 | 1,880,093 | ||
| Deferred tax liabilities | 79,612 | 83,946 | ||
| Operating lease liabilities | 94,687 | 101,828 | ||
| Other liabilities | 139,792 | 122,298 | ||
| Total liabilities | 3,084,830 | 2,766,084 | ||
| Redeemable noncontrolling interests | 145,543 | 117,116 | ||
| Equity: | ||||
| Common stock | 904 | 918 | ||
| Additional paid-in capital | 2,701,663 | 2,685,464 | ||
| Retained earnings | 375,419 | 387,333 | ||
| Total equity | 3,077,986 | 3,073,715 | ||
| Total liabilities and equity | $ | 6,308,359 | $ | 5,956,915 |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 7
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||||
|---|---|---|---|---|---|---|
| Condensed Consolidated Statements of Cash Flows | ||||||
| (Unaudited) | ||||||
| Six Months Ended June 30, | ||||||
| --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | |||||
| (In thousands) | ||||||
| Operating activities: | **** | **** | **** | **** | **** | **** |
| Net income | $ | 47,000 | $ | 159,587 | ||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | **** | **** | **** | **** | **** | **** |
| Depreciation and amortization | 96,027 | 72,413 | ||||
| Amortization of debt issuance costs | 2,278 | 2,034 | ||||
| Equity-based compensation expense | 19,226 | 17,547 | ||||
| Deferred income taxes | (8,753 | ) | 39,017 | |||
| Debt extinguishment costs | 1,269 | — | ||||
| Legal settlements expense | 3,504 | — | ||||
| Loss on impairment | 1,452 | 1,000 | ||||
| Gain on sale of property | (8,715 | ) | — | |||
| Other | 1,128 | (3,942 | ) | |||
| Change in operating assets and liabilities, net of effect of acquisitions: | ||||||
| Accounts receivable, net | (42,660 | ) | (26,114 | ) | ||
| Other current assets | (3,797 | ) | (14,182 | ) | ||
| Other assets | (7,684 | ) | 842 | |||
| Accounts payable and other accrued liabilities | 27,684 | (399,619 | ) | |||
| Accrued salaries and benefits | (3,940 | ) | (8,525 | ) | ||
| Other liabilities | 20,962 | 9,805 | ||||
| Net cash provided by (used in) operating activities | 144,981 | (150,137 | ) | |||
| Investing activities: | **** | **** | **** | **** | **** | **** |
| Cash paid for acquisitions, net of cash acquired | (8,165 | ) | (50,722 | ) | ||
| Cash paid for capital expenditures | (342,378 | ) | (296,652 | ) | ||
| Proceeds from sale of property and equipment | 16,623 | 10,209 | ||||
| Other | (101 | ) | (2,933 | ) | ||
| Net cash used in investing activities | (334,021 | ) | (340,098 | ) | ||
| Financing activities: | **** | **** | **** | **** | **** | **** |
| Borrowings on long-term debt | 1,200,000 | 350,000 | ||||
| Borrowings on revolving credit facility | 830,000 | 160,000 | ||||
| Principal payments on revolving credit facility | (1,035,000 | ) | (15,000 | ) | ||
| Principal payments on long-term debt | (4,063 | ) | (25,605 | ) | ||
| Repayment of long-term debt | (670,856 | ) | — | |||
| Payment of debt issuance costs | (18,615 | ) | (1,518 | ) | ||
| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises | (3,716 | ) | (1,668 | ) | ||
| Repurchase of common stock | (50,034 | ) | — | |||
| Contributions from noncontrolling partners in joint ventures | — | 2,970 | ||||
| Distributions to noncontrolling partners in joint ventures | (1,990 | ) | (1,500 | ) | ||
| Cash paid for contingent consideration | (1,500 | ) | — | |||
| Other | (70 | ) | (350 | ) | ||
| Net cash provided by financing activities | 244,156 | 467,329 | ||||
| Net increase (decrease) in cash and cash equivalents | 55,116 | (22,906 | ) | |||
| Cash and cash equivalents at beginning of the period | 76,305 | 100,073 | ||||
| Cash and cash equivalents at end of the period | $ | 131,421 | $ | 77,167 | ||
| Effect of acquisitions: | **** | **** | **** | **** | **** | **** |
| Assets acquired, excluding cash | $ | 19,881 | $ | 55,678 | ||
| Liabilities assumed | (842 | ) | (3,456 | ) | ||
| Contingent consideration issued in connection with an acquisition | — | (1,500 | ) | |||
| Redeemable noncontrolling interest resulting from an acquisition | (10,874 | ) | — | |||
| Cash paid for acquisitions, net of cash acquired | $ | 8,165 | $ | 50,722 |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 8
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Statistics ^^^(1)^ | ||||||||||||||
| (Unaudited, $ in thousands except per Patient Day metrics) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | |||||||||
| Same Facility Results ^(2)^ | ||||||||||||||
| Revenue | $ | 851,223 | $ | 777,680 | 9.5 | % | $ | 1,610,920 | $ | 1,522,102 | 5.8 | % | ||
| Patient Days | 789,619 | 775,772 | 1.8 | % | 1,553,577 | 1,523,166 | 2.0 | % | ||||||
| Admissions | 49,903 | 49,226 | 1.4 | % | 98,410 | 96,729 | 1.7 | % | ||||||
| Average Length of Stay ^(3)^ | 15.8 | 15.8 | 0.4 | % | 15.8 | 15.7 | 0.3 | % | ||||||
| Revenue per Patient Day | $ | 1,078 | $ | 1,002 | 7.5 | % | $ | 1,037 | $ | 999 | 3.8 | % | ||
| Adjusted EBITDA | $ | 256,019 | $ | 224,335 | 14.1 | % | $ | 447,624 | $ | 434,914 | 2.9 | % | ||
| Total Facility Results | ||||||||||||||
| Revenue | $ | 869,232 | $ | 796,040 | 9.2 | % | $ | 1,639,737 | $ | 1,564,091 | 4.8 | % | ||
| Patient Days | 804,840 | 791,673 | 1.7 | % | 1,579,773 | 1,560,351 | 1.2 | % | ||||||
| Admissions | 51,922 | 50,511 | 2.8 | % | 101,605 | 99,569 | 2.0 | % | ||||||
| Average Length of Stay^^^(3)^ | 15.5 | 15.7 | -1.1 | % | 15.5 | 15.7 | -0.8 | % | ||||||
| Revenue per Patient Day | $ | 1,080 | $ | 1,006 | 7.4 | % | $ | 1,038 | $ | 1,002 | 3.5 | % | ||
| Adjusted EBITDA | $ | 240,397 | $ | 224,035 | 7.3 | % | $ | 412,758 | $ | 434,961 | -5.1 | % | ||
| ^(1)^ Total facility and same facility results may not be indicative of the overall performance of our business and should not be considered as alternatives for net income or any other performance measures in accordance with GAAP (as defined herein). | ||||||||||||||
| --- | ||||||||||||||
| ^(2)^ Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | ||||||||||||||
| ^(3)^^^Average length of stay is defined as patient days divided by admissions. |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 9
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA and<br> Same Facility Adjusted EBITDA | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | 2025 | 2024 | |||||||||
| (in thousands) | ||||||||||||
| Net income attributable to Acadia Healthcare Company, Inc. | $ | 30,127 | $ | 78,482 | $ | 38,501 | $ | 154,865 | ||||
| Net income attributable to noncontrolling interests | 7,809 | 2,335 | 8,499 | 4,722 | ||||||||
| Provision for income taxes | 12,067 | 25,643 | 16,471 | 45,717 | ||||||||
| Interest expense, net | 35,138 | 29,159 | 64,320 | 56,373 | ||||||||
| Depreciation and amortization | 48,995 | 36,066 | 96,027 | 72,413 | ||||||||
| EBITDA | 134,136 | 171,685 | 223,818 | 334,090 | ||||||||
| Adjustments: | ||||||||||||
| Equity-based compensation expense (a) | 10,549 | 8,869 | 19,226 | 17,547 | ||||||||
| Transaction, legal and other costs (b) | 64,425 | 6,091 | 95,497 | 8,938 | ||||||||
| Debt extinguishment costs (c) | — | — | 1,269 | — | ||||||||
| Legal settlements expense (d) | — | — | 3,504 | — | ||||||||
| Loss on impairment (e) | 1,452 | 1,000 | 1,452 | 1,000 | ||||||||
| Gain on sale of property (f) | (8,715 | ) | — | (8,715 | ) | — | ||||||
| Adjusted EBITDA | $ | 201,847 | $ | 187,645 | $ | 336,051 | $ | 361,575 | ||||
| Corporate general and administrative costs (g) | (38,550 | ) | (36,390 | ) | (76,707 | ) | (73,386 | ) | ||||
| Total Facility Adjusted EBITDA | 240,397 | 224,035 | 412,758 | 434,961 | ||||||||
| De novos, acquisitions, and closed facilities (h) | (15,622 | ) | (300 | ) | (34,866 | ) | 47 | |||||
| Same Facility Adjusted EBITDA | $ | 256,019 | $ | 224,335 | $ | 447,624 | $ | 434,914 | ||||
| See footnotes on pages 11-12. | ||||||||||||
| --- |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 10
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to | ||||||||||
| Adjusted Income Attributable to Acadia Healthcare Company, Inc. | ||||||||||
| (Unaudited) | ||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | 2025 | 2024 | |||||||
| (in thousands, except per share amounts) | ||||||||||
| Net income attributable to Acadia Healthcare Company, Inc. | $ | 30,127 | $ | 78,482 | $ | 38,501 | $ | 154,865 | ||
| Adjustments to income: | ||||||||||
| Transaction, legal and other costs (b) | 64,425 | 6,091 | 95,497 | 8,938 | ||||||
| Debt extinguishment costs (c) | — | — | 1,269 | — | ||||||
| Legal settlements expense (d) | — | — | 3,504 | — | ||||||
| Loss on impairment (e) | 1,452 | 1,000 | 1,452 | 1,000 | ||||||
| Gain on sale of property (f) | (8,715 | ) | — | (8,715 | ) | — | ||||
| Provision for income taxes | 12,067 | 25,643 | 16,471 | 45,717 | ||||||
| Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. | 99,356 | 111,216 | 147,979 | 210,520 | ||||||
| Income tax effect of adjustments to income (i) | 24,516 | 27,643 | 36,210 | 49,654 | ||||||
| Adjusted income attributable to Acadia Healthcare Company, Inc. | 74,840 | 83,573 | 111,769 | 160,866 | ||||||
| Weighted-average shares outstanding - diluted | 90,435 | 92,043 | 91,400 | 92,051 | ||||||
| Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share | $ | 0.83 | $ | 0.91 | $ | 1.22 | $ | 1.75 | ||
| See footnotes on pages 11-12. | ||||||||||
| --- |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 11
August 5, 2025
| Acadia Healthcare Company, Inc. | |
|---|---|
| Footnotes | |
| We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows: | |
| • EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization. | |
| • Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, debt extinguishment and legal settlements expense. | |
| • Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, debt extinguishment, legal settlements expense and provision for income taxes. | |
| • Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income. | |
| • Total facility adjusted EBITDA: Adjusted EBITDA adjusted for general and administrative costs related to our corporate functions. General and administrative costs directly related to the facilities are included in total facility results. | |
| • Same facility adjusted EBITDA: Adjusted EBITDA for facilities and services to those facilities operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired, divested or removed from service during the current or prior year. | |
| The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. | |
| Total facility results include operating results for all of our facilities and services but exclude general and administrative costs related to our corporate functions. Such costs related to our corporate functions include, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. General and administrative costs directly related to the facilities are included in facility results. Such costs directly related to our facilities include, amongst others, labor at the facility level, insurance, including property, professional, legal and general liability insurance, hospital supplies, including medication, utilities and food service, and general maintenance costs for the facility. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Note that total facility costs include those related to new facilities and the cost of closure and run-out costs related to facilities we have closed. We believe that providing results on a total facility basis is helpful to our investors as a measure of our financial and operating performance because it neutralizes the impact of corporate-level items that do not arise out of our core operations at our facilities. | |
| Same facility results include operating results only for facilities and services operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired during the current or prior year, as well as facilities divested or removed from service. We believe that providing results on a same facility basis is helpful to investors because it neutralizes the impact of new facilities that are in early stages of operation and facilities that we no longer operate, each of which may distort investors’ understanding of the Company’s underlying performance at our existing and continuing facilities. Further, we believe that providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. For these reasons, we believe that same facility results are particularly useful during periods of significant expansion or contraction. | |
| Total facility results reflect adjustments that are intended to provide the specific presentation described above, and same facility results reflect adjustments that may be irregular in timing from period to period related to newly opened or acquired facilities or facilities that we no longer operate, and may omit certain results that investors may view as important. Total facility and same facility results may therefore not be indicative of the overall performance of our business and should be not be considered as alternatives for net income or any other performance measures derived in accordance with GAAP. | |
| The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. |
- MORE -
ACHC Reports Second Quarter 2025 Results
Page 12
August 5, 2025
| Acadia Healthcare Company, Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Footnotes (continued) | ||||||||||
| (a) Represents the equity-based compensation expense of Acadia. Equity-based compensation expense is excluded from Adjusted EBITDA because Acadia believes that the cost of equity awards granted to employees does not contribute to the earnings potentially available for distributions to its equity holders or reinvestment into its business. | ||||||||||
| (b) Represents transaction, legal, and other costs incurred by Acadia primarily related to the following categories: (1) government investigations; (2) termination and restructuring costs; (3) legal, accounting, and other acquisition-related costs; and (4) management transition costs. Government investigations include legal fees and settlement costs related to certain litigation. Termination and restructuring costs include costs, net of gains, incurred related to workforce reductions, contract amendments, and the closure and disposition of certain facilities, including related lease terminations. Legal, accounting and other acquisition-related costs include costs incurred for the development of new facilities ($0.4 million and $1.3 million for the three and six months ended June 30, 2025, respectively, and $1.4 million and $2.0 million for the three and six months ended June 30, 2024, respectively); legal and settlement costs incurred related to certain litigation not included in Government Investigations ($0.4 million and $(2.6) million for the three and six months ended June 30, 2025, respectively, and $0.4 million and $4.4 million for the three and six months ended June 30, 2024, respectively); and direct costs associated with acquisitions ($0.2 million and $0.4 million for the three and six months ended June 30, 2024, respectively). Management transition costs include certain costs associated with the transition of the leadership team, including the design and implementation of the revised organizational structure. Management transition costs incurred with the transition of our Chief Executive Officer beginning in the first quarter of 2022 concluded in the fourth quarter of 2024. The table below quantifies each of the components of transaction, legal and other costs for the periods presented. Such transaction, legal and other costs are excluded from Adjusted EBITDA because Acadia believes that the nature, size, and number of these costs can vary dramatically from period to period and between Acadia and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult. | ||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | 2025 | 2024 | |||||||
| (in thousands) | ||||||||||
| Government investigations | $ | 53,526 | $ | 2,051 | $ | 84,538 | $ | 2,532 | ||
| Termination and restructuring costs | 10,074 | 1,419 | 12,239 | (1,981 | ) | |||||
| Legal, accounting and other acquisition-related costs | 825 | 2,034 | (1,280 | ) | 6,791 | |||||
| Management transition costs | — | 587 | — | 1,596 | ||||||
| Transaction, legal, and other costs | $ | 64,425 | $ | 6,091 | $ | 95,497 | $ | 8,938 | ||
| (c) Represents debt extinguishment costs recorded during the first quarter of 2025 in connection with the refinancing of the prior credit facility. Debt extinguishment is excluded from Adjusted EBITDA because Acadia believes that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results. | ||||||||||
| --- | ||||||||||
| (d) Represents legal settlements expense related to costs associated with the Desert Hills litigation. Legal settlements expense is excluded from Adjusted EBITDA because Acadia believes that this expense is unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results. | ||||||||||
| (e) Represents non-cash impairment charges related to the closure of certain facilities. Non-cash impairment charges related to the closure of certain facilities are excluded from Adjusted EBITDA because Acadia believes that these charges are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results. | ||||||||||
| (f) Represents gain on facility property sale. Gains from facility property sales are excluded from Adjusted EBITDA because Acadia believes that these gains are unrelated to Acadia’s day-to-day business operations and not indicative of Acadia’s ongoing operating results. | ||||||||||
| (g) Represents general and administrative costs related to our corporate functions, including, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Corporate general and administrative costs are excluded to present Total Facility Adjusted EBITDA because we believe that providing results on a total facility basis is helpful to our investors as a measure of the financial and operating performance of our core operations at our facilities. | ||||||||||
| (h) Represents the portion of EBITDA for the periods presented attributable to de novos and acquired facilities in operation for less than one year and facilities closed during such period. De novos are newly developed facilities built by Acadia or with a joint venture partner. Such amounts are excluded from Adjusted EBITDA to present Same Facility Adjusted EBITDA because we believe providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. | ||||||||||
| (i) Represents the income tax effect of adjustments to income based on tax rates of 24.7% and 24.9% for the three months ended June 30, 2025 and 2024, respectively, and 24.5% and 23.6% for the six months ended June 30, 2025 and 2024, respectively. We believe excluding the income tax effect of adjustments to income assists investors in understanding the tax provision associated with those adjustments and the effect on net income. | ||||||||||
| Investor Contact: | ||||||||||
| Patrick Feeley | ||||||||||
| Senior Vice President, Investor Relations | ||||||||||
| (615) 861-6000 |
- END -